

Editor's Note

As the editorial office for *Pharmacological Reviews* turns over, we want to recognize our past successes and keep you, the readers and contributors, up-to-date.

First, we need to recognize the efforts of Darrell Abernethy, who completed his term as Editor-in-Chief on January 1, 2007. Darrell has worked tirelessly to maintain both the standards and the impact of *Pharmacological Reviews*. During the transition of the editorship to us, both the quantity and quality of his efforts have become increasingly clear. Many thanks, and well done!

The goal in 2007 is to maintain and build upon Darrell's efforts. The quality of the journal clearly depends on the quality of the contributions and the efforts of our authors and reviewers. We will make a special effort to publish reviews on areas likely to have a high impact over the next 5 years and to continue the participation of thought-leaders in these areas as authors. We are reviewing a range of possible format changes, including focusing on more concise reviews and using commentaries that precede reviews to help put them concisely into perspective. We will keep you informed of our progress.

The editorial office has moved back to the ASPET office in Bethesda, Maryland under the capable direction of Jill Filler. We hope the move will improve the efficiency of proposal and manuscript handling, and we will be aiming to significantly reduce our turnaround time over the next year.

During this transition, we look forward to the comments of our readers and look forward to continuing the distinguished tradition of *Pharmacological Reviews* as the preeminent review journal in the field.

Ross Feldman, M.D.
Editor